A Randomized, Open-Label Study to Assess the Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis.
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Natalizumab (Primary) ; Keyhole limpet haemocyanin; Tetanus toxoid
- Indications Multiple sclerosis; Tetanus
- Focus Pharmacodynamics
- Sponsors Biogen
- 14 Apr 2011 Results presented at the 63rd Annual Meeting of the American Academy of Neurology.
- 28 Oct 2010 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 17 Jun 2009 Planned end date changed from Oct 2009 to Jan 2010 as reported by ClinicalTrials.gov.